Zeo ScientifiX, Inc. Overview
Pro stress-test →Zeo ScientifiX, Inc. is a clinical-stage biopharmaceutical company focusing on the development of biological therapeutics for the treatment of degenerative diseases and regenerative medicines. The company's therapeutic platform focuses on regenerative biologics, specifically extracellular vesicle (exosome) therapeutics and next-generation delivery systems designed to target the underlying biological mechanisms of aging and inflammation.
Strategic Profile
Pro stress-test →As of July 2025, ZEO is spearheading an expansion initiative aligned with Florida's new SB-1768 stem cell law, with Florida now authorizing the use of non-FDA-approved stem cell therapies compliant with the new regulations. In April 2026, the company was selected as a Qualified Team advancing into the Semi-Finals stage of the XPRIZE Healthspan, a $101 million global competition designed to revolutionize human aging.
Competitive Landscape
Pro stress-test →Zeo operates in the regenerative medicine and clinical-stage biotech space, competing with cell therapy companies and autologous biologic developers. The company has a strategic collaboration with Regen Therapy Limited for biologic therapeutics development. Primary competitors include broader cell therapy platforms (Orgenesis, Celularity) and regenerative medicine developers targeting degenerative diseases.
Industry Context
Zeo ScientifiX, Inc. operates in Clinical-stage regenerative biologics and exosome therapeutics.
Key facts
Founded: 2011 · Headquarters: Davie, Florida · Revenue: $5.55M · Market cap: $14.8M